/HBP.TO
HBP.TO Stock - Helix BioPharma Corp.
Healthcare|BiotechnologyTSX
$2.29+5.05%
+$0.11 (+5.05%) • Dec 22
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.83
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.52
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HBP.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.27 – $2.31
TARGET (TP)$2.63
STOP LOSS$2.11
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.63
52W High$5.40
52W Low$0.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-10,000 | $-14,000 | $-13,000 | $-12,000 | $-173,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-5,425,000 | $-9,371,000 | $-6,279,000 | $-6,537,000 | $-9,611,000 |
| Net Income | $-5,205,000 | $-9,264,000 | $-6,290,000 | $-6,080,000 | $-7,911,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.09 | $-0.21 | $-0.16 | $-0.20 | $-0.29 |
Company Overview
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HBP.TOBeat Rate
0%
Last 1 quarters
Avg Surprise
+0.0%
EPS vs Estimate
Beats / Misses
0/0
1 met exactly
Latest EPS
$-0.01
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q4 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q4 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 12, 2026 | — | — | — | — |
Q4 2025 | Dec 12, 2025 | — | $-0.01 | — | — |
Q4 2025 | Oct 16, 2025 | — | $-0.01 | — | — |
Q2 2025 | Jun 16, 2025 | — | $-0.15 | — | — |
Q1 2025 | Mar 14, 2025 | — | $-0.14 | — | — |
Q4 2024 | Dec 12, 2024 | — | $-0.14 | — | — |
Q4 2024 | Oct 24, 2024 | — | $-0.11 | — | — |
Q2 2024 | May 13, 2024 | — | $-0.04 | — | — |
Q2 2024 | Apr 16, 2024 | — | $-0.02 | — | — |
Q4 2023 | Dec 14, 2023 | — | $-0.03 | — | — |
Q4 2023 | Oct 27, 2023 | — | $-0.05 | — | — |
Q2 2023 | Jun 14, 2023 | — | $-0.03 | — | — |
Q1 2023 | Mar 15, 2023 | — | $-0.03 | — | — |
Q4 2022 | Dec 14, 2022 | — | $-0.05 | — | — |
Q4 2022 | Oct 31, 2022 | — | $-0.04 | — | — |
Q2 2022 | Jun 14, 2022 | — | $-0.04 | — | — |
Q1 2022 | Mar 16, 2022 | — | $-0.07 | — | — |
Q4 2021 | Dec 15, 2021 | — | $-0.06 | — | — |
Q4 2021 | Dec 9, 2021 | — | $-0.09 | — | — |
Q2 2021 | Jun 14, 2021 | $-0.02 | $-0.02 | 0.0% | = MET |
Latest News
Loading news...
Frequently Asked Questions about HBP.TO
What is HBP.TO's current stock price?
Helix BioPharma Corp. (HBP.TO) is currently trading at $2.29 per share. The stock has moved +5.05% today.
What is the analyst price target for HBP.TO?
No analyst price targets are currently available for this stock.
What sector is Helix BioPharma Corp. in?
Helix BioPharma Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSX exchange.
What is HBP.TO's market cap?
Helix BioPharma Corp. has a market capitalization of $0.17 billion, making it a small-cap company.
Does HBP.TO pay dividends?
No, Helix BioPharma Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRDL.TO
Cardiol Therapeutics Inc.
$1.40
Mkt Cap: $0.1B
CYBN.NE
Cybin Inc.
$9.79
Mkt Cap: $0.2B
HLS.TO
HLS Therapeutics Inc.
$4.75
Mkt Cap: $0.1B
JUSH.CN
Jushi Holdings Inc.
$0.76
Mkt Cap: $0.1B
LOVE.V
Cannara Biotech Inc.
$1.71
Mkt Cap: $0.2B
MDNA.TO
Medicenna Therapeutics Corp.
$0.99
Mkt Cap: $0.1B
MSCL.TO
Satellos Bioscience Inc.
$0.66
Mkt Cap: $0.1B
QIPT.TO
Quipt Home Medical Corp.
$4.84
Mkt Cap: $0.2B
RVX.TO
Resverlogix Corp.
$0.10
Mkt Cap: $0.0B
SVA.TO
Sernova Corp.
$0.14
Mkt Cap: $0.0B
Explore stocks similar to HBP.TO for comparison